One injectable gel, five medical markets: Inside Australia’s most versatile medtech
Tetratherix built a $255 million ASX company around a single injectable polymer. Now that same material is being used in everything from dental surgery to prostate cancer treatment and GLP-1 delivery. Tetratherix grabbed the market’s attention in March when it announced its patented polymer was going to be used for the slow release of GLP-1 […]